Drug Profile
OMT 28
Alternative Names: 17,18-epoxyeicosatetraenoic acid analog; OMT-28Latest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator OMEICOS Therapeutics
- Class Antiarrhythmics; Cardiovascular therapies; Eicosanoids; Omega 3 fatty acids; Small molecules
- Mechanism of Action Nitric oxide stimulants; Peroxisome proliferator-activated receptor alpha agonists; Phosphatidylinositol 3 kinase gamma modulators; Protein kinase stimulants; Proto oncogene protein c akt modulators; Sirtuin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Atrial fibrillation; Cardiomyopathies; Inflammation; Musculoskeletal disorders
- Preclinical Wet age-related macular degeneration
- No development reported Myocardial infarction
Most Recent Events
- 27 Mar 2023 Phase-II clinical trials in Cardiomyopathies in Germany (PO) (EudraCT2022-003307-16)
- 27 Mar 2023 Phase-II clinical trials in Inflammation in Germany (PO) (EudraCT2022-003307-16)
- 27 Mar 2023 Phase-II clinical trials in Musculoskeletal disorders in Germany (PO) (EudraCT2022-003307-16)